Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6616 to 6630 of 8213 results

  1. COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Evidence summary: COVID-19 rapid summary
    Published
    21 May 2020

  2. COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Evidence summary: COVID-19 rapid summary
    Published
    21 May 2020

  3. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Evidence summary: COVID-19 rapid summary
    Published
    14 April 2020

  4. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Evidence summary: COVID-19 rapid summary
    Published
    21 May 2020

  5. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Technology appraisal guidance
    Published
    28 August 2019

  6. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  7. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Medtech innovation briefing
    Published
    15 June 2018

  8. Utrasound-guided foam sclerotherapy for varicose veins (IPG314)

    This guidance has been updated and replaced by NICE interventional procedure guidance 440.

    Interventional procedures guidance
    Published
    23 August 2009

  9. Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG309)

    This guidance has been updated and replaced by NICE interventional procedure guidance 649.

    Interventional procedures guidance
    Published
    26 August 2009

  10. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Evidence summary
    Published
    12 May 2021

  11. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE interventional procedures guidance 793.

    Interventional procedures guidance
    Published
    22 June 2016

  12. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Technology appraisal guidance
    Published
    23 July 2001

  13. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Evidence summary
    Published
    24 June 2014

  14. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789. 

    Interventional procedures guidance
    Published
    24 February 2010

  15. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016